(Q35183728)

7 August 2017

1 reference

title

Recommendations for the treatment of fungal pneumonias (English)

1 reference

7 August 2017

Harumi Yamada

1

1 reference

7 August 2017

Hajime Kotaki

series ordinal

2

1 reference

7 August 2017

Takashi Takahashi

series ordinal

3

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 August 2003

1 reference

Expert Opinion on Pharmacotherapy

7 August 2017

published in

1 reference

7 August 2017

volume

4

1 reference

7 August 2017

issue

8

1 reference

7 August 2017

page(s)

1241-1258

1 reference

Use of fiberoptic bronchoscopy in bone marrow transplant recipients

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

Community-acquired pneumonia: etiology, epidemiology, and outcome at a teaching hospital in Argentina

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

Pulmonary fungal infection: emphasis on microbiological spectra, patient outcome, and prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

Practice guidelines for the treatment of fungal infections. For the Mycoses Study Group. Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

Practice guideline for the treatment of coccidioidomycosis. Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

Antifungal use in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

The assessment of immunologic and clinical changes occurring during corticosteroid therapy for allergic bronchopulmonary aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

Adjunctive Therapy of Allergic Bronchopulmonary Aspergillosis with Itraconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

Allergic bronchopulmonary aspergillosis in cystic fibrosis: role of atopy and response to itraconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

Clinical utility of monitoring serum cryptococcal antigen (sCRAG) titers in patients with AIDS-related cryptococcal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

Pulmonary disease caused by Candida species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

Paracoccidioidomycosis: a model for evaluation of the effects of human immunodeficiency virus infection on the natural history of endemic tropical diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

Amphotericin B and itraconazole for treatment of disseminated Penicillium marneffei infection in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

Penicillium marneffei: types and drug susceptibility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

Pretreatment regimens for adverse events related to infusion of amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

Unusual lipid structures selectively reduce the toxicity of amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

Clinical pharmacokinetics of systemic antifungal drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

Lipid formulations of amphotericin B: clinical efficacy and toxicities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

Clinical use of liposomal and lipid-complexed amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

21 January 2018

New antifungal agents

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

Review of the safety and efficacy of voriconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

Voriconazole: a new triazole antifungal agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

Caspofungin: an echinocandin antifungal agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

Single- and multiple-dose pharmacokinetics of caspofungin in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

Safety and tolerability of caspofungin acetate in the treatment of fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

Caspofungin acetate for treatment of invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

In vivo activity of micafungin in a persistently neutropenic murine model of disseminated infection caused by Candida tropicalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.8.1241

10.1517/14656566.4.8.1241

21 January 2018

Identifiers

DOI

1 reference

release_l2qu3fd6y5b65oa6lbjha4byeu

7 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/l2qu3fd6y5b65oa6lbjha4byeu

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference